American Century Companies Inc. Acquires 120,905 Shares of Eli Lilly and Company

Pharmaceutical giant Eli Lilly sees increased institutional investment

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

American Century Companies Inc., a major investment management firm, has increased its stake in pharmaceutical company Eli Lilly and Company by acquiring an additional 120,905 shares during the third quarter. This represents a 6.6% increase in American Century's holdings of Eli Lilly stock, which now totals nearly 2 million shares valued at over $1.4 billion.

Why it matters

The increase in institutional investment from a firm like American Century Companies is a positive sign for Eli Lilly, as it suggests growing confidence in the company's long-term prospects among major investors. Eli Lilly is one of the world's leading pharmaceutical companies, with a diverse portfolio of innovative drugs and a strong pipeline of new treatments.

The details

According to a recent SEC filing, American Century Companies Inc. now owns 1,961,645 shares of Eli Lilly, making it one of the company's largest institutional investors. The additional 120,905 shares were acquired during the third quarter of the year. Eli Lilly makes up about 0.8% of American Century's overall investment portfolio.

  • American Century Companies Inc. acquired the additional 120,905 shares of Eli Lilly during the third quarter of 2026.

The players

American Century Companies Inc.

A major investment management firm that has increased its stake in pharmaceutical company Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana, that researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

Got photos? Submit your photos here. ›

The takeaway

The increased investment from a prominent firm like American Century Companies is a positive sign for Eli Lilly, as it suggests growing confidence in the company's long-term prospects among major institutional investors. This could signal continued growth and innovation for the pharmaceutical giant.